In contrast to the expression of these activating receptors, we find no significantly altered expression of the inhibitory receptors NKG2A, killer-cell immunoglobulin-like receptor (KIR) or KLRG1 on NK cells from CLL patients (see supplemental Fig. 2, Supplemental Digital Content). This evidence concerns the gene KIR3DL2 and B-cell chronic lymphocytic leukemia.